Skip to main content

Table 1 Clinical characteristics of AAV patients at diagnosis

From: Atherogenic index of plasma predicts cerebrovascular accident occurrence in antineutrophil cytoplasmic antibody-associated vasculitis

Variables

All AAV patients

(N = 167)

AAV patients with AIP < 0.11

(N = 115)

AAV patients with AIP ≥ 0.11

(N = 52)

P-value

Demographic data

 Age (years)

59.0 (22.0)

60.0 (24.0)

56.0 (19.8)a

0.369

 Male gender (N, (%))

54 (32.3)

34 (29.6)

20 (38.5)

0.255

 Body mass index (kg/m2)

22.1 (4.5)a

22.0 (4.8)a

23.2 (4.3)a

0.324

 Smoking history (N, (%))

6 (3.6)

3 (2.6)

3 (5.8)

0.310

AAV Subtypes (N, (%))

   

0.641

 MPA

92 (55.1)

64 (55.7)

28 (53.8)

 

 GPA

38 (22.8)

24 (20.9)

14 (26.9)

 

 EGPA

37 (22.2)

27 (23.5)

10 (19.2)

 

ANCA positivity (N, (%))

 MPO-ANCA (or P-ANCA) positivity

114 (68.3)

79 (68.7)

35 (67.3)

0.858

 PR3-ANCA (or C-ANCA) positivity

27 (16.2)

16 (13.9)

11 (21.2)

0.239

 Both ANCA positivity

8 (4.8)

6 (5.2)

2 (3.8)

1.000

 ANCA negativity

34 (20.4)

26 (22.6)

8 (15.4)

0.283

AAV-specific indices

 BVAS

12.0 (11.0)a

12.0 (11.0)a

14.0 (10.0)a

0.041

 FFS

1.0 (1.0)

1.0 (1.0)

1.0 (1.0)

0.656

Clinical manifestations (N, (%))

 General

75 (44.9)

48 (41.7)

27 (51.9)

0.221

 Cutaneous

38 (22.8)

29 (25.2)

9 (17.3)

0.259

 Muco-membranous /Ocular

10 (6.0)

5 (4.3)

5 (9.6)

0.184

 Ear nose throat

75 (44.9)

51 (44.3)

24 (46.2)

0.828

 Pulmonary

97 (58.1)

69 (60.0)

28 (53.8)

0.455

 Cardiovascular

43 (25.7)

27 (23.5)

16 (30.8)

0.318

 Gastrointestinal

9 (5.4)

7 (6.1)

2 (3.8)

0.553

 Renal

104 (62.3)

69 (60.0)

35 (67.3)

0.367

 Nervous

56 (33.5)

38 (33.0)

18 (34.6)

0.842

Comorbidities (N, (%))

 Chronic kidney disease (stage 3–5)

53 (31.7)

33 (28.7)

20 (38.5)

0.209

 Diabetes mellitus

51 (30.5)

35 (30.4)

16 (30.8)

0.965

 Hypertension

89 (53.3)

57 (49.6)

32 (61.5)

0.151

 Interstitial lung disease

50 (29.9)

36 (31.3)

14 (26.9)

0.567

Laboratory results

 White blood cell count (/mm3)

9210.0 (6347.5)

9180.0 (6430.0)

10,230.0 (6000.0)

0.927

 Hemoglobin (g/dL)

11.3 (2.3)a

11.4 (2.3)a

11.0 (2.5)a

0.235

 Platelet count (×  1000/mm3)

308.0 (166.0)

311.0 (158.5)

294.0 (195.0)

0.949

 Fasting glucose (mg/dL)

104.0 (36.0)

103.0 (34.0)

106.0 (38.0)

0.466

 BUN (mg/dL)

18.4 (22.4)

18.0 (23.0)

24.2 (21.6)

0.078

 Creatinine (mg/dL)

1.0 (1.3)

0.9 (1.0)

1.3 (2.0)

0.105

 Total serum protein (g/dL)

6.6 (1.3)

6.7 (1.1)

6.4 (1.0)a

0.043

 Serum albumin (g/dL)

3.5 (0.8)a

3.5 (0.7)a

3.3 (0.8)a

0.068

 ALP (IU/L)

72.0 (38.0)

69.0 (36.0)

77.0 (51.0)

0.339

 AST (IU/L)

18.5 (9.0)

19.0 (8.0)

17.0 (10.0)

0.121

 ALT (IU/L)

16.5 (14.8)

15.0 (13.5)

19.0 (18.0)

0.985

 Total bilirubin (mg/dL)

0.5 (0.3)

0.5 (0.3)

0.5 (0.4)

0.620

 ESR (mm/hr)

64.0 (69.3)

64.0 (67.0)

66.8 (39.6)a

0.406

 CRP (mg/L)

17.0 (85.8)

15.0 (69.3)

25.0 (119.3)

0.123

AIP-related variables

 Total cholesterol (mg/dL)

178.0 (58.0)

182.1 (45.8)a

187.0 (58.1)a

0.561

 TG (mg/dL)

113.0 (73.0)

97.5 (35.5)a

174.5 (67.8)

< 0.001

 HDL-cholesterol (mg/dL)

51.0 (23.0)

55.0 (25.0)

41.4 (14.6)a

< 0.001

 LDL-cholesterol (mg/dL)

104.6 (41.6)

106.0 (33.1)a

102.2 (45.1)

0.917

 AIP

−0.01 (0.2)a

− 0.1 (0.3)

0.3 (0.1)a

< 0.001

  1. Values are expressed as a median (interquartile range) or N (%)
  2. AAV ANCA-associated vasculitis, ANCA Antineutrophil cytoplasmic antibody, AIP Atherogenic index of plasma, MPA Microscopic polyangiitis, GPA Granulomatosis with polyangiitis, EGPA Eosinophilic GPA, MPO Myeloperoxidase, P Perinuclear, PR3 Proteinase 3, C Cytoplasmic, BVAS Birmingham vasculitis activity score, FFS Five-factor score, BUN Blood urea nitrogen, ALP Alkaline phosphatase, AST Aspartate aminotransferase, ALT Alanine aminotransferase, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, TG Triglyceride, HDL High-density lipoprotein, LDL Low-density lipoprotein
  3. a Normally distributed data are expressed as mean (standard deviation)